Heron Therapeutics Sees Large Volume Increase (HRTX)

Heron Therapeutics (NASDAQ:HRTX)’s share price reached a new 52-week high during mid-day trading on Wednesday after Leerink Swann raised their price target on the stock from $38.00 to $57.00, AnalystRatings.NET reports. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $5.43. The 52-week high of Heron Therapeutics, Inc. As per the latest information, Brean Capital Raises the price target to $55.00 per share from a prior target of $45.00.

On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The director of Heron Therapeutics, Inc. Heron Therapeutics has a one year low of $6.51 and a one year high of $42.25. In a report issued on August 17, Cowen analyst Boris Peaker reiterated a Buy rating on HRTX, with a price target of $47, which represents a potential upside of 35.6% from where the stock is now trading. They set a “buy” rating and a $46.00 target price on the stock. The stock’s 50-day moving average is $34.56 and its 200-day moving average is $24.45.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.09. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Equities research analysts anticipate that Heron Therapeutics will post ($2.80) EPS for the current fiscal year.

AcelRx Pharmaceuticals Inc, Innocoll AG, Insys Therapeutics Inc and Ocular Therapeutix Inc are among companies developing rival post-operative painkillers.

HTX-011, which uses the company’s Biochronomer drug delivery technology, reduced pain intensity by 69% in 24 hours and by 40% in 72 hours, Heron said. APF530 contains the 5-HT3 antagonist granisetron formulated in the Companys Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

Heron has also run a phase two trial of the pain drug in hemorrhoidectomy patients, which it expects to report on in a matter of weeks. The Company’s other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.